An Open-Label Study to Assess the Hepatic Protection Effect of SNP-612, in Patients With NAFLD

NCT03868566 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

90

Enrollment

INDUSTRY

Sponsor class

Stopped recruitment difficulties due to Covid-19

Conditions

NASH - Nonalcoholic Steatohepatitis

Interventions

DRUG: SNP-612 dose1
DRUG: SNP-612 dose2

Sponsor

Sinew Pharma Inc.